Table 1 Key results from phase III trials of HPV vaccines
Vaccine name | Gardasil ® | Cervarix ® |
|---|---|---|
Time of follow-up | 36 months (advanced) | 15 months (interim) |
HPV types included | 6, 11, 16, 18 | 16, 18 |
Efficacy HPV 16 or 18 CIN 2+ | Proven | Proven |
Efficacy HPV 16 CIN 2+ | Proven | Proven |
Efficacy HPV 18 CIN 2+ | Proven | Not yet provena |
Efficacy 16 or 18 CIN 2 | Proven | Proven |
Efficacy 16 or 18 CIN 3 | Proven | Not yet provena |
Therapeutic efficacy | None | None |
Efficacy on VIN 2/3 | Proven | Not yet reported |
Efficacy on VAIN 2/3 | Proven | Not yet reported |
Efficacy on genital warts | Proven | Not in target |
Safety at 6 years follow-up | Safeb | Safec |
Tolerability | Acceptable | Acceptable |
Cross protection (persistent HPV infection) | 6 months | 12 months |
Cross protection (lesions) | Reported | Not yet reported |
Duration of protectiond | 5–6 years | 5–6 years |
Immunogenicity in preadolescents | Proven | Proven |
Immunogenicity in older women | Proven | Proven |
Immune memory at 6 years | Proven | Not yet reported |
